glp 1 ra cardiovascular benefits Mechanisms by which GLP-1 agonists may exert beneficial effects on the Cardiovascular benefits of glucagon-like peptide-1

GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone

[email protected] (R.T.)

While this approach can support sustainable weight management with fewer side effects, it remains off-label and lacks robust clinical data

Back Mojsov, Svetlana emails to Lara Marks, Dec 2024, March 2025

Fruits & veggies should ideally be a staple in the diet for this reason

It offers a gentle alternative for super-responders, those managing conditions like PCOS, or anyone simply trying to avoid debilitating side effects while navigating a broken system marked by high costs and shortages